IFRX חוב כולל להון InflaRx
German biopharmaceutical developer InflaRx N.V. (IFRX) focuses on developing C5a antibodies for the therapy of severe inflammation and rare pathologies, currently conducting final clinical trials. This chart of share prices on GURU.Markets demonstrates a total debt-to-equity ratio of 0.01. The company's financial stability relies on current sales of treatments for viral complications and the upcoming launch of innovative drugs.
פילוחים אנליטיים ודוחות נתונים של חברת InflaRx (IFRX)
Within the biotechnology sector, InflaRx N.V. focuses on attracting Germany's leading immunologists, which requires sustainable funding for R&D processes. By analyzing the total liabilities-to-equity ratio, an investor assesses the proportion of borrowed funds within the balance sheet structure, where an increase in the metric indicates credit risks, while its minimum reflects conservative capital management to preserve scientific independence.